FrancophonIA/ELRC3.0 huggingface dataset:
English: The revisions concern the fees for consultation on line-extensions for ancillary substances, including blood derivates, incorporated in medical devices; and the implementation of the new regulation on maximum residue limits.
Slovenian: Spremembe se nanašajo na pristojbine za posvetovanje o razširitvi indikacij za pomožne snovi, kamor sodijo tudi krvni derivati, vključeni v medicinske pripomočke, in izvajanje nove uredbe o najvišjih mejnih vrednosti ostankov.
English: The CHMP has provided an explanatory note about the rationale for benefit-risk assessment of the vaccines, and published the information on the Agency's website.
Slovenian: Odbor za zdravila za uporabo v humani medicini je predložil pojasnilo z utemeljitvijo ocene razmerja med koristjo in tveganjem cepiv in informacijo objavil na spletni strani agencije.
English: The Board was invited to send comments with regards to the outlined proposal ahead of its presentation in December.
Slovenian: Upravni odbor je bil pozvan, naj predloži pripombe v zvezi z osnutkom predloga pred njegovo predstavitvijo v decembru.
English: The first discussion on the draft road map at the HMA level is planned for later this year, in time to submit the document for discussion at the EMEA Management Board in December.
Slovenian: Prva razprava o osnutku časovnega načrta na ravni vodij agencij za zdravila je predvidena enkrat v tem letu, a dovolj zgodaj, da bo dokument lahko predložen v razpravo na seji upravnega odbora agencije EMEA v decembru.
English: [EMEA/MB/320040/2009] Summary of transfers of appropriations in the budget 2009.
Slovenian: [EMEA/MB/320040/2009] Povzetek prenosov dodeljenih sredstev v proračun za leto 2009.
English: The Management Board proposed to invite the chair of the HMPC to present the work of the Committee and the challenges it encounters at its December meetings.
Slovenian: Upravni odbor je predlagal, naj se na decembrsko sejo povabi predsednik odbora HMPC, da predstavi delo odbora in izzive, s katerimi se spopada.
English: Report on interaction with patients' organisations
Slovenian: Poročilo o sodelovanju z organizacijami bolnikov
English: The experience with the revised CV template will be reviewed in the future.
Slovenian: Izkušnje s spremenjeno predlogo življenjepisa bodo pregledane na prihodnjih sestankih.
English: [EMEA/MB/517929/2009] The Board adopted the proposals aiming to improve the consultation process on nomination of scientific committee members.
Slovenian: [EMEA/MB/517929/2009] Upravni odbor je sprejel predloge, katerih namen je izboljšati posvetovalni postopek imenovanja članov znanstvenega odbora.
English: The Agency's current road map covers the period up to 2010.
Slovenian: Dolgoročna strategija agencije EMEA - Časovni načrt Sedanji časovni načrt agencije zajema obdobje do leta 2010.
English: Fergus Sweeney Mario Benetti Claus Christiansen Hans-Georg Eichler Anne-Sophie Henry-Eude Xavier Luria Arielle North Nerimantas Steikūnas Spiros Vamvakas
Slovenian: Fergus Sweeney Mario Benetti Claus Christiansen Hans-Georg Eichler Anne-Sophie Henry-Eude Xavier Luria
English: [EMEA/MB/517930/2009] Outcome of written procedures: - On consultation on changes in the membership of the CHMP and CVMP scientific committees; - Final accounts 2008; - Minutes of the 64th meeting of the Management Board;
Slovenian: [EMEA/MB/517930/2009] Rezultat pisnih postopkov o: - posvetovanju o spremembah članstva v odborih CHMP in CVMP; - zaključnem računu za leto 2008; - zapisniku štiriinšestdesete seje upravnega odbora; - spremembi proračuna 01-2009.
English: [EMEA/433259/2009] The Board noted the outcome of the written procedure on consultation on the nomination to the CVMP and considered the nomination as insufficient.
Slovenian: [EMEA/433259/2009] Upravni odbor se je seznanil s pisnim postopkom o posvetovanju o imenovanju v Odbor za zdravila za uporabo v veterinarski medicini (CVMP) in menil, da je kandidatura pomanjkljiva.
English: [EMEA/MB/366757/2009] The Management Board noted the adoption of the minutes by written procedure on 28 July 2009.
Slovenian: [EMEA/MB/366757/2009] Upravni odbor se je seznanil s sprejetjem zapisnika s pisnim postopkom z dne 28. julija 2009.
English: Vacancy notice for the Executive Director's function
Slovenian: Objava prostega delovnega mesta za položaj izvršnega direktorja
English: [EMEA/MB/589426/2009] The Board further considered the proposal on contractual arrangements following the discussion in June and a subsequent round of consultation.
Slovenian: [EMEA/MB/589426/2009] Upravni odbor je dodatno proučil predlog o pogodbeni ureditvi po junijski razpravi in naknadnem posvetovanju.
English: EMEA/MB/642672/2009/EN/Adopted 13 November 2009
Slovenian: EMA/MB/151648/2010/SL/sprejeto 13. novembra 2009
English: [EMEA/MB/565964/2009] The Board also noted the proposed future amendment of the fee implementing rules in relation to the new legislation on variations.
Slovenian: [EMEA/MB/565964/2009] Upravni odbor se je tudi seznanil s predlagano spremembo izvedbenih pravil o pristojbinah v povezavi z novo zakonodajo o spremembah.
English: [EMEA/MB/503751/2009] The Management Board reviewed the progress of the implementation of the Agency's work programme 2009.
Slovenian: [EMEA/MB/503751/2009] Upravni odbor je pregledal izvajanje delovnega programa agencije v letu 2009.
English: [EMEA/MB/575748/2009] The Board noted the mandate and the report on the first year of operation of the Ad Hoc Pharmacovigilance Inspectors Working Group.
Slovenian: [EMEA/MB/575748/2009] Upravni odbor se je seznanil s pristojnostmi in poročilom o prvem letu delovanja ad hoc delovne skupine inšpektorjev za farmakovigilanco.
English: Management Board members reviewed and provided written comments on the proposed vacancy notice for the Executive Director's post.
Slovenian: Člani upravnega odbora so pregledali predlagano objavo prostega delovnega mesta izvršnega direktorja in predložili pisne pripombe.
English: [EMEA/MB/170391/2009/Rev.3] The Management Board adopted the revisions to the fee implementing rules.
Slovenian: [EMEA/MB/170391/2009/Rev.3] Upravni odbor je sprejel spremembe izvedbenih pravil o pristojbinah.
English: Minutes from the 63rd meeting, held on 11 June 2009
Slovenian: Zapisnik triinšestdesete seje, ki je potekala 11. junija 2009
English: Representative of veterinarians' organisations
Slovenian: Predstavniki organizacij veterinarjev
English: [EMEA/MB/589426/2009] The Management Board noted the report on interaction with patients' and consumers' organisations.
Slovenian: [EMEA/MB/589426/2009] Upravni odbor se je seznanil s poročilom o sodelovanju z organizacijami bolnikov in potrošnikov.
English: − Pat O'Mahony;
Slovenian: Pata O'Mahonyja,
English: A proposed framework on the interaction with HCPs' organisations will be discussed at the October meeting of the working group.
Slovenian: Delovna skupina bo o predlaganem okviru sodelovanja z organizacijami zdravstvenih strokovnjakov razpravljala na oktobrski seji.
English: The Board asked to convene the committee and present its terms of reference at the December meeting.
Slovenian: Upravni odbor je zaprosil za sklic odbora in predstavitev njegovih pristojnosti ter nalog na decembrski seji.
English: EMEA/MB/569756/2009] Reports on EudraVigilance implementation for human medicines and medicines for veterinary use.
Slovenian: [EMEA/MB/472819/2009*; EMEA/MB/569756/2009] Poročila o izvajanju sistema EudraVigilance za zdravila, namenjena uporabi v humani medicini in veterinarski medicini.
English: [A6-0162_2009_EN] European Parliament decision on discharge to the Executive Director of the EMEA [EMEA/MB/528743/2009] Update report on EMEA implementation of EU telematics strategy.
Slovenian: [A6-0162_2009_EN] Sklep Evropskega parlamenta o razrešnici izvršnemu direktorju agencije EMEA.
English: The authority will then decide whether to continue with the nomination in the light of the feedback received from the Agency.
Slovenian: Organ bo nato glede na povratno informacijo agencije odločil, ali naj postopek imenovanja nadaljuje.
English: Representative of doctors' organisations
Slovenian: Predstavniki organizacij zdravnikov
English: Lisette Engwirda-Tiddens
Slovenian: Lisette Tiddens-Engwirda
English: The composition of the new MBTC is as follows:
Slovenian: Sestava novega usmerjevalnega odbora z telematiko pri upravnem odboru agencije EMEA je:
English: − Thomas Lönngren;
Slovenian: Agencija EMEA je imenovala naslednje predstavnike: Thomasa Lönngrena;
English: [EMEA/MB/472819/2009*;
Slovenian: [EMEA/69619/2009].
English: [EMEA/69619/2009] The Management Board adopted the 2009 part of the telematics master plan.
Slovenian: Upravni odbor je sprejel del glavnega načrta za telematiko za leto 2009.
English: The Board nominated the following members:
Slovenian: Upravni odbor je imenoval naslednje člane: Marcusa Müllnerja;
English: Invented name Strength Pharmaceutical Form Route of Administration Packaging
Slovenian: Izmišljeno ime Jakost
English: --1 Each dose (0.007 ml) of undiluted vaccine contains: - Eimeria acervulina, strain 003 - 332-450 sporulated oocysts - Eimeria maxima, strain 013 - 196 - 265 sporulated oocysts - Eimeria mitis, strain 006 - 293 - 397 sporulated oocysts - Eimeria praecox, strain 007 - 293 - 397 sporulated oocysts - Eimeria tenella, strain 004 - 276-374 sporulated oocysts
Slovenian: --1 En odmerek (0,007 ml) nerazredčenega cepiva vsebuje: - Eimeria acervulina, sev 003 - 332-450 sporuliranih oocist - Eimeria maxima, sev 013 - 196-265 sporuliranih oocist - Eimeria mitis, sev 006 - 293-397 sporuliranih oocist - Eimeria praecox, sev 007 - 293-397 sporuliranih oocist - Eimeria tenella, sev 004 - 276-374 sporuliranih oocist
English: The full EPAR for Pioglitazone Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pioglitazone Teva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pioglitazone Teva on 26 March 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Pioglitazone Teva, veljavno po vsej Evropski uniji, odobrila dne 26. marca 2012.
English: Treatment with Pioglitazone Teva should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit.
Slovenian: Zdravljenje z zdravilom Pioglitazone Teva je treba ponovno oceniti po treh do šestih mesecih in ga pri bolnikih, ki od njega nimajo zadostne koristi, prekiniti.
English: For more information about treatment with Pioglitazone Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Pioglitazone Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The active substance in Pioglitazone Teva, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Slovenian: Zdravilna učinkovina zdravila Pioglitazone Teva, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
English: This means that Pioglitazone Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
English: Pioglitazone Teva is a ‘generic medicine'.
Slovenian: Pioglitazone Teva je „generično zdravilo“.
English: This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Slovenian: Priporočeni začetni odmerek zdravila Pioglitazone Teva je 15 ali 30 mg enkrat na dan. Odmerek bo po enem ali dveh tednih morda treba povečati do 45 mg enkrat na dan, če je potreben boljši nadzor glukoze (sladkorja) v krvi.
English: This is a summary of the European public assessment report (EPAR) for Pioglitazone Teva.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pioglitazone Teva.
English: What are the benefits and risks of Pioglitazone Teva?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Pioglitazone Teva?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pioglitazone Teva.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Pioglitazone Teva, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Because Pioglitazone Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Pioglitazone Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The CHMP concluded that, in accordance with EU requirements, Pioglitazone Teva has been shown to have comparable quality and to be bioequivalent to Actos.
Slovenian: CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pioglitazone Teva primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
English: Pioglitazone Teva is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Slovenian: Zdravilo Pioglitazone Teva se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
English: Other information about Pioglitazone Teva
Slovenian: Druge informacije o zdravilu Pioglitazone Teva
English: Because Pioglitazone Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Slovenian: Ker je zdravilo Pioglitazone Teva generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
English: Pioglitazone Teva is a medicine that contains the active substance pioglitazone.
Slovenian: Pioglitazone Teva je zdravilo, ki vsebuje zdravilno učinkovino pioglitazon.
English: The Committee recommended that Pioglitazone Teva be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Pioglitazone Teva odobri dovoljenje za promet.
English: Pioglitazone Teva should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease).
Slovenian: Zdravilo Pioglitazone Teva se ne sme uporabljati pri bolnikih na dializi (tehniki čiščenja krvi, ki se uporablja pri bolnikih z obolenjem ledvic).
English: Pioglitazone Teva can also be used together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
Slovenian: Zdravilo Pioglitazone Teva se lahko uporablja tudi skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadostno nadzorovana zgolj z insulinom in za katere metformin ni primeren.
English: Pioglitazone Teva is used on its own in patients for whom metformin (another antidiabetes medicine) is not suitable.
Slovenian: Zdravilo Pioglitazone Teva se uporablja kot samostojno zdravilo pri bolnikih, za katere metformin (drugo zdravilo proti sladkorni bolezni) ni primeren.
English: Pioglitazone Teva can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy').
Slovenian: Zdravilo Pioglitazone Teva se lahko uporablja tudi v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče doseči zadovoljivega nadzora, ali v kombinaciji s sulfonilsečnino (drugo vrsto zdravila proti sladkorni bolezni), če metformin ni primeren (zdravljenje z dvema zdraviloma).
English: Why has Pioglitazone Teva been approved?
Slovenian: Zakaj je bilo zdravilo Pioglitazone Teva odobreno?
English: Pioglitazone Teva can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy').
Slovenian: Zdravilo Pioglitazone Teva se lahko uporablja tudi skupaj z metforminom in sulfonilsečnino hkrati pri bolnikih, pri katerih nadzor ni zadosten kljub dvojnemu peroralnemu zdravljenju (zdravljenje s tremi zdravili).
English: How has Pioglitazone Teva been studied?
Slovenian: Kako je bilo zdravilo Pioglitazone Teva raziskano?
English: What is Pioglitazone Teva?
Slovenian: Kaj je zdravilo Pioglitazone Teva?
English: What is Pioglitazone Teva used for?
Slovenian: Za kaj se zdravilo Pioglitazone Teva uporablja?
English: How is Pioglitazone Teva used?
Slovenian: Kako se zdravilo Pioglitazone Teva uporablja?
English: How does Pioglitazone Teva work?
Slovenian: Kako zdravilo Pioglitazone Teva deluje?
English: It is, therefore, unlikely that you will be given too much.
Slovenian: Zato je malo verjetno, da bi vam ga dali preveč.
English: This is called ‘overgrowth' or ‘superinfection'.
Slovenian: To se imenuje razraščanje ali superinfekcija.
English: These can develop suddenly and can potentially be life-threatening.
Slovenian: Do njih lahko pride nenadno in so lahko tudi smrtno nevarne.
English: Via Morolense, 5 03013 Ferentino (FR) Italy
Slovenian: Via Morolense, 5 03013 Ferentino (FR)
English: A course of treatment usually lasts for 4 to 14 days.
Slovenian: Zdravljenje običajno traja od 4 do 14 dni.
English: Your doctor will decide how long you should be treated for.
Slovenian: Zdravnik bo določil, koliko časa naj traja zdravljenje.
English: The safety and efficacy of Xerava in children and adolescents less than 18 years of age have not been established.
Slovenian: Varnost in učinkovitost zdravila Xerava pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
English: Ferentino Italy
Slovenian: Ferentino Italija
English: If not, it may be stored at room temperature and used within 12 hours.
Slovenian: Če je ne prejmete takoj, jo je mogoče shraniti pri sobni temperaturi in uporabiti v naslednjih 12 urah.
English: This medicine should not be used in children and adolescents under the age of 18 years as it has not been studied enough in these populations.
Slovenian: To zdravilo se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let, saj pri teh populacijah ni dovolj proučeno.
English: In these cases, no recommendation on a posology can be made.
Slovenian: V teh primerih ni mogoče podati priporočila o odmerjanju.
English: Eravacycline is not genotoxic.
Slovenian: Eravaciklin ni genotoksičen.
English: 100 mL 250 mL 250 mL 250 mL 500 mL 500 mL
Slovenian: 100 ml 250 ml 250 ml 250 ml
English: • Losing consciousness
Slovenian: • izguba zavesti.
English: Read all of this leaflet carefully before you receive this medicine because it contains important information for you.
Slovenian: Pred začetkom prejemanja zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
English: Other appropriate measures should be taken and alternative antimicrobial treatment should be considered in accordance with existing therapeutic guidelines.
Slovenian: Izvesti je treba druge ustrezne ukrepe in premisliti o drugih možnostih protimikrobnega zdravljenja v skladu z obstoječimi terapevtskimi smernicami.
English: If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine.
Slovenian: Če ste noseči, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom, preden prejmete to zdravilo.
English: Eravacycline is administered intravenously and therefore has 100% bioavailability.
Slovenian: Eravaciklin se daje intravensko in je zato 100-odstotno biološko razpoložljiv.
English: • delay the natural formation of the bones of your unborn child.
Slovenian: • zakasni naravno tvorbo kosti nerojenega otroka.
English: Interactions with medicinal products that are substrates for these enzymes or transporters are therefore unlikely.
Slovenian: Zato medsebojno delovanje z drugimi zdravili, ki niso substrati za te encime ali prenašalce, ni verjetno.
English: Dublin 2, D02 T380, Ireland
Slovenian: Dublin 2, D02 T380, Irska
English: Do not use this medicine after the expiry date which is stated on the vial label and carton after ‘EXP'.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki na viali in škatli poleg oznake „EXP“.
English: Component of a multipack, can't be sold seperately.
Slovenian: Del skupnega pakiranja, ne sme se prodajati ločeno.
English: • permanently stain your unborn child's teeth
Slovenian: • trajno obarva zobe nerojenega otroka;
English: 1.0 mg/kg IV every 12 hours (n=6) Day 1 2125 (15) Day 10 1825 (16)
Slovenian: vsakih 12 ur (n = 6) 1. dan 2125 (15) 10. dan 1825 (16)
English: These findings were reversible or partially reversible during recovery periods of 3- to 7-weeks.
Slovenian: Ti ugotovljeni izvidi so bili v obdobju okrevanja od treh do sedmih tednov reverzibilni ali delno reverzibilni.
English: - if you are allergic to eravacycline or any of the other ingredients of this medicine (listed in section 6).
Slovenian: − če ste alergični na eravaciklin ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Slovenian: • Redna posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
English: These include sensitivity to light, headaches, vision problems, or abnormal blood tests.
Slovenian: Med njimi so občutljivost za svetlobo, glavoboli, težave z vidom ali nenormalni krvni testi.
English: No data are available for patients weighing more than 137 kg.
Slovenian: O bolnikih, ki tehtajo več kot 137 kg, ni podatkov.
English: Number of vials to needed to reconstitute
Slovenian: Število vial, potrebnih za rekonstitucijo
English: In case of serious reactions, eravacycline should be discontinued until a new intravenous access site is established.
Slovenian: Pri resnih reakcijah je treba dajanje eravaciklina prekiniti, dokler ni določeno novo intravensko dostopno mesto.
English: Although antibiotics including Xerava fight certain bacteria, other bacteria and fungi may continue to grow.
Slovenian: Čeprav antibiotiki, vključno z zdravilom Xerava, delujejo na določene bakterije, lahko druge bakterije in glive še naprej rastejo.
English: - if you are allergic to any tetracycline antibiotics (e.g., minocycline and doxycycline) because you may also be allergic to eravacycline.
Slovenian: − če ste alergični na kateri koli tetraciklinski antibiotik (npr. minociklin in doksiciklin), ker ste morda alergični tudi na eravaciklin.
English: If not used immediately, in-use storage times and conditions are the responsibility of the user.
Slovenian: Če zdravilo ni uporabljeno takoj, je za čas shranjevanja in pogoje med uporabo odgovoren uporabnik.
English: If superinfection occurs during therapy, it may require interruption of treatment.
Slovenian: Če med zdravljenjem pride do superinfekcij, je zaradi tega morda treba prekiniti zdravljenje.